MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis
Istesso Limited, the programmed disease resolution company, today announces the...
6th September 2022
Potential of Istesso’s MBS2320 hits the headlines
Istesso Limited (“Istesso’’) was featured on Thisismoney.co.uk over the weekend,...
30th August 2022
MBS2320 Phase 2a headline results announced
Istesso Limited (“Istesso’’) today announces headline results from the Phase...
15th July 2019
Positive outcome from Phase 1 study of MBS2320
Istesso announces positive outcome from patient cohort in Phase 1...
30th August 2017